DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC)
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
radiotherapy,durvalumab,squamous cell carcinoma,open-label,non-resectable,hpv-negative,la-hnscc
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要